Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826227 | 0.89 | CTSL (0.52) | CTSLP2RX7ENPP1ALDH1A1LMNA | |
| SCHEMBL1824792 | 0.87 | P2RX7 (0.56) | CTSLP2RX7ENPP1ALDH1A1LMNA | |
| SCHEMBL1826839 | 0.85 | ACACB (0.54) | P2RX7ENPP1ALDH1A1MEN1KMT2A | |
| SCHEMBL1825634 | 0.85 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL1825120 | 0.83 | ALDH1A1 (0.55) | P2RX7ENPP1ALDH1A1LMNAMEN1 | |
| SCHEMBL1824172 | 0.81 | P2RX7 (0.46) | P2RX7ENPP1ALDH1A1LMNA | |
| SCHEMBL1822286 | 0.81 | P2RX7 (0.52) | P2RX7ENPP1KDM4EKDM4A | |
| SCHEMBL1825424 | 0.79 | ALDH1A1 (0.58) | P2RX7ENPP1ALDH1A1LMNAMEN1 | |
| SCHEMBL1826230 | 0.78 | P2RX7 (0.46) | P2RX7ENPP1 | |
| SCHEMBL12029124 | 0.77 | CTRB1 (0.71) | CTSLALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161254-B1 | Intermediate for preparing a biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-1481967-B1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-2161254-A1 | Intermediate for preparing a biaryl compound | Sumitomo Chemical Company, Limited (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1481967-A1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | CTSL 4133/4885P2RX7 3606/4885ENPP1 3768/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | CTSL 2260/4885P2RX7 2747/4885ENPP1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.